banner news

Singapore, April 9, 2019 – Credo Diagnostics Biomedical Pte. Ltd.,a groundbreaking molecular diagnostic company, announced today they will attend the China East and West Small Animal Clinical Veterinary Conference that will take place at the Xiamen International Conference & Exhibition Center from May 21 to May 23.


Credo Diagnostics Biomedical will be introducing its revolutionary point-of-care molecular diagnostic solution, the QubeMDx, for the first time to the Veterinary community in China. Using a proprietary Real Time PCR technology, the QubeMDx is an affordable, accurate requires little to no training to provide diagnostic results in only 15 minutes from a variety of sample types (feces, blood, oral fluid, etc.). The current companion animal diagnostic menu includes more than 20 targets including Canine Babesiosis panel, Canine Ehrlichiosis/Anaplasmosis panel, and Feline Haemobartonellosis panel.


Credo Diagnostics Biomedical will be located at the Hall C3 booth #A14, where it will be meeting with individual veterinarians, scholars, veterinary associations, and potential business partners.


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics Biomedical develops, and manufactures innovative, cost-effective, and rapid Molecular Diagnostic solutions at the Point-of-Care (POC) in the areas of Animal Health, Human Health, and Human Wellness. By providing the right information, at the right time, and to the right people, we can improve the lives of billions of people and animals around the world.



We at Credo Diagnostics Biomedical pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.